The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1666
December 26, 2022
View Complete Issue         Table of Contents 2019 
Risankizumab (Skyrizi) - An IL-23 Antagonist for Crohn's Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Risankizumab (Skyrizi) - An IL-23 Antagonist for Crohn's Disease
December 26, 2022 (Issue: 1666)
The injectable interleukin (IL)-23 antagonist risankizumab-rzaa (Skyrizi – Abbvie) has been approved by the FDA for treatment of moderately to severely active Crohn's disease (CD) in adults. Risankizumab was approved earlier for treatment...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Risankizumab (Skyrizi) - An IL-23 Antagonist for Crohn's Disease
Article code: 1666c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.